Priority Research Papers:
AMP-activated kinase (AMPK) regulates activity of HER2 and EGFR in breast cancer
Metrics: PDF 2658 views | HTML 2691 views | ?
Teraneh Z. Jhaveri1, Juhyung Woo1, Xiaobin Shang1, Ben Ho Park1 and Edward Gabrielson1
1 Departments of Pathology and Oncology, The Sydney Kimmel Cancer Center, The Johns Hopkins School of Medicine, Baltimore, MD, USA
Edward Gabrielson, email:
Keywords: AMP-activated protein kinase (AMPK); HER2; EGFR; cancer cell metabolism; cancer therapy
Received: May 20, 2015 Accepted: June 01, 2015 Published: June 15, 2015
AMP-activated Protein Kinase (AMPK) activity retards growth of many types of cancers. Investigating effects of AMPK activation on breast cancer cell signaling and survival, we found that breast cancer cell lines with amplification and over-expression of HER2 or EGFR are 2- to 5-fold more sensitive to cytotoxic effects of AICAR, a canonical pharmacological activator of AMPK, than breast cancer cell lines lacking HER2 or EGFR overexpression. Paralleling effects on cell survival, AICAR leads to dose- and time-dependent inhibition of HER2 and EGFR in HER2-amplified breast cancer cells, with activation of AMPK and suppression of HER2/ EGFR activity preceding commitment to cell death. Transfection of constitutively active AMPKα also leads to decreased HER2 and EGFR phosphorylation, reduced downstream signaling associated with these receptor tyrosine kinases (RTKs), and reduced breast cancer cell growth, confirming effects of AMPK activity on HER2/ EGFR. Ensuing co-immunoprecipitation experiments demonstrated an interaction of HER2 with AMPK and an in vitro phosphorylation assay found that HER2 and EGFR contain sequences that are potential substrates for AMPK. Our results lead us to postulate that AMPK regulates HER2 and EGFR activity in HER2-amplified breast cancer cells and thus activation of AMPK might provide therapeutic benefit in such cancers.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.